Short Summary
The Bombay High Court dismissed the plaintiff's motion seeking an interim injunction in a passing off suit. The court found that the trade marks, including those with the prefix 'CEF,' are commonly used across the pharmaceutical industry. Given the prevalence of similar prefixes and suffixes derived from chemical compounds like Cefixime, the court held that the plaintiff failed to establish exclusivity or reputation for their mark, thus denying the injunction.
Detailed Summary
In the fiercely competitive pharmaceutical industry, brand names can make or break a product. But what happens when a company tries to claim ownership over a prefix that every other player in the market is already using? The Bombay High Court's decision in the Medley Pharmaceuticals vs Khandelwal Laboratories case serves as a powerful reminder that not every recognizable word or syllable can be monopolized, especially when it originates from a widely-used chemical compound.
Medley Pharmaceuticals Ltd., the plaintiff, approached the court seeking an interim injunction against Khandelwal Laboratories Ltd. in a passing off suit. The dispute centered on trademarks that shared the prefix 'CEF,' a prefix commonly derived from the chemical compound Cefixime, a well-known antibiotic used across the pharmaceutical industry. Medley Pharmaceuticals claimed that Khandelwal Laboratories' use of similar 'CEF'-prefixed marks amounted to passing off, essentially arguing that consumers would be confused into believing the products were theirs. The plaintiff sought to halt the defendant's use of these marks pending the resolution of the suit.
Medley Pharmaceuticals argued that their 'CEF'-prefixed trademarks had acquired distinctiveness and reputation in the market, giving them exclusive rights to use this prefix in connection with their pharmaceutical products. They contended that the defendant's adoption of similar marks would mislead consumers and dilute their brand identity. On the other side, Khandelwal Laboratories countered that the 'CEF' prefix was not unique to Medley at all. The defendant pointed out that this prefix was derived from the chemical name Cefixime and was commonly used across the pharmaceutical industry by numerous manufacturers. The core legal friction thus revolved around a fundamental question: can a company claim proprietary rights over a prefix that is essentially a public chemical reference, widely adopted by competitors?
The Bombay High Court dismissed Medley Pharmaceuticals' motion for an interim injunction, ruling decisively in favor of Khandelwal Laboratories. The court found that trademarks bearing the 'CEF' prefix are commonly used across the pharmaceutical industry, reflecting the widespread adoption of prefixes and suffixes derived from chemical compounds like Cefixime. Critically, the court held that Medley Pharmaceuticals had failed to establish exclusivity or reputation for their mark. Because the prefix was generic to the industry and not distinctive to any single player, the plaintiff could not demonstrate the kind of proprietary claim necessary to succeed in a passing off action. The interim injunction was denied, allowing Khandelwal Laboratories to continue using their similar marks.
For founders and IP professionals in the pharmaceutical space, this case delivers a clear and actionable lesson: do not rely on common chemical prefixes or suffixes to build your brand identity. When a prefix is derived from a widely-used chemical compound like Cefixime, it is considered part of the industry's common vocabulary, and no single company can claim exclusive ownership over it. To build a protectable trademark, invest in distinctive, coined, or arbitrary elements that set your brand apart, rather than leaning on generic chemical references. In passing off actions, courts will look for evidence of genuine exclusivity and reputation, not just prior use of a universally adopted prefix. Choose your marks wisely, because in pharma, the chemistry of branding is just as important as the chemistry of your product.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in trademark matters before Bombay High Court. Understanding the court's reasoning in Medley Pharmaceuticals Ltd. vs Khandelwal Laboratories Ltd. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Mahesh Namkeen Pvt. Ltd.vsOm Prakash Nebhwani (Trading as: Mahesh Matar Namkeen)
Mahesh Namkeen Pvt. Ltd., a Lucknow-based company engaged in manufacturing namkeens and snacks since 1983 under the trademark 'MAHESH' (with parrot device), sued Om Prakash Nebhwani for trademark infringement and passing off. The defendant, who is the nephew of the plaintiff's director and had prior knowledge of the mark, adopted the identical 'MAHESH' mark with parrot/peacock device for his own namkeen business in Jaipur. The defendant's defense was struck off for non-filing of written statement. The court found the plaintiff's mark to be distinctive, well-established, and a well-known trademark, and held that the defendant's use constituted slavish copying amounting to infringement and passing off.
Ms Pas AgrovsM/S Krbl Limited & Anr
Ms Pas Agro has filed a petition under Section 124(1)(b)(ii) of the Trademarks Act challenging the Commercial Court's order dismissing its application to frame a preliminary issue on the invalidity of KRBL's registered trademark 'INDIA GATE' (application no. 599833). The underlying suit CS (COMM) 78/2025 was filed by KRBL against Pas Agro. The Delhi High Court issued notice, permitted deletion of respondent no.2, and granted time for filing reply and rejoinder. The substantive question of whether a preliminary issue on trademark invalidity should be framed remains pending.
Cryogas Equipment Private LimitedvsInox India Limited & Ors.
The Supreme Court disposed of a miscellaneous application seeking extension of time for the trial court to decide Trademark Suit No. 3 of 2019 between Cryogas Equipment Private Limited and Inox India Limited. As a last opportunity, the Court granted an additional six months to the concerned court to decide the suit, while expressly warning that no further extension would be entertained. The underlying dispute concerns trademark rights in the cryogenic/industrial gas equipment sector.
Mankind Consumer Products Private LimitedvsAlaina Healthcare Private Limited & A. Menarini India Private Limited
Mankind Consumer Products, the registered proprietor of the trademark ACNESTAR (Reg. No. 1352577 in Class 5) since 2005, sued Alaina Healthcare and A. Menarini India for using the marks ACNE SCAR/ACNE+SCAR/ACNESCAR on their acne scar serum product HEXILAK. The court found a prima facie case of deceptive similarity, noting that the dominant feature 'ACNE' was common and the suffix 'STAR' vs 'SCAR' was insufficient to distinguish the marks, especially given the identical trade channels and consumer class. The court granted an interim injunction in favour of the plaintiff while allowing defendant no. 2 a two-month period to recall existing stock from the trade.
Healthium Medtech Limited (earlier Healthium Medtech Private Limited)vsThe Registrar of Trade Marks, Chennai
Healthium Medtech Limited filed a writ petition seeking a mandamus to compel the Registrar of Trade Marks to expeditiously dispose of Opposition No. 1027536 filed by Glenmark Pharmaceuticals against Healthium's trademark application No. 4270882 for the 'Healthium' device mark in Classes 05 and 10. The petitioner complained that despite evidence having been adduced, the opposition proceedings remained pending without a final hearing. The Madras High Court allowed the writ petition and directed the Registrar to hear both parties and dispose of the opposition on merits within four weeks.
CavinKare Private LimitedvsMaha Aqua, Trading As Mahalakshmi Aqua
CavinKare Private Limited filed a trademark infringement suit against Maha Aqua (trading as Mahalakshmi Aqua) seeking a permanent injunction to restrain the defendant from using the mark 'MAA' or any deceptively similar mark in respect of goods in Class 32. The plaintiff relies on its registered trademarks 'MAA' under Nos. 1109946 and 6453733. The Court, after issues were framed and affidavits of admission/denial filed, approved a Joint Case Management Schedule suggested by both parties and set timelines for completion of evidence and oral arguments.
Facing a trademark dispute?
Arctic's TM litigation team handles ~120 trademark matters per year across India, EU, and UK. From oppositions to infringement actions, we build winning arguments from precedent.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.